The FDA issued a statement that Raptiva was being voluntarily withdrawn from the market by its manufacturer Genentech.
Raptiva is a once weekly injection for adults with moderate to severe plaque psoriasis. However, recent studies have shown that Raptiva may increase the risk of developing progressive multifocal leukoencephalopathy (PML). PML is a rare, but serious, progressive neurologic disease caused by a virus that affects the central nervous system and is most common in individuals immune difficiency disorders such as AIDS.
Patients should speak to their physician immediately about alternatives to Raptiva. If they have developed PML or other neurological disorders during the course of use of Raptiva, they may have a cause of action and should contact an attorney to review their case.
Comments for this article are closed.